Lilly dives into vaccine research with 3 biotech buyouts
Worth close to $4 billion combined, the acquisitions of Curevo, LimmaTech and Vaccine Co. signal plans by Lilly to build an infectious disease portfolio.
Read the full article on the original site.
Read Full Article